Clinicogen is currently developing tests for a number of types of cancer where we believe molecular tests can make a significant impact in improving patient care and lowering costs.
Clinicogen has developed a blood based Real Time PCR molecular assay, TheraleadTM CRC. In clinical studies of both CRC and healthy patients the assay has been shown to be highly sensitive (92%) and highly specific (95%) when directly compared to colonoscopy results
Clinicogen is a GenoSensor, Inc. owned company started to focus on development and commercialization, either directly or through partners, of molecular assays for clinical applications. The company is specifically focused on cancer diagnostics for both screening and early detection as well as for monitoring the effectiveness of therapy.
Genetic information and nucleic acid technology are playing an increasingly important role in the effective and efficient delivery of medical care. The monitoring of genes and their activities have been shown to accurately reveal individual health and disease conditions. Clinicogen is focused on developing molecular techniques for early identification of cancers and the monitoring of the effectiveness of treatment. Our technological core focuses on identifying and detecting genes in human blood and fluid samples
Biomarkers for use in colorectal cancer
By Dr. Xueliang James Xia
Published on December 18, 2018
United States Patent 10,155,991
The present invention provides assays, methods and kits that may be used to assess colorectal cancer (CRC) in a subject in relation to diagnosis, prognosis and treatment evaluation, using blood samples.